Serologic markers in early stages of African horse sickness virus infection

Martı́nez-Torrecuadrada, Jorge L.; Diaz-Laviada, M.; Roy, P; Sánchez, C; Vela, Carmen; Sánchez-Vizcaíno, J M; Casal, J. Ignacio

doi:10.1128/jcm.35.2.531-535.1997

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A. House et al., 1992, 1994; Lelli et al., 2013; Lulla et al., 2017; Martínez‐Torrecuadrada et al., 1996, 1997; Minke et al., 2012; Mirchamsy & Taslimi, 1964a, 1964b, 1968; Ozawa & Bahrami, 1966; Ozawa et al., 1965, 1970; Quan et al., 2010; Roy et al., 1996; Scanlen et al., 2002; Stone‐Marschat et al., 1996; van Rijn et al., 2018; von Teichman et al., 2010; Whitworth, 1930). These included all serotypes apart from AHSV‐7 and two studies where the serotype was unidentified (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

Re‐parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search

Fairbanks

Mertens

Tildesley

et al. 2022

Transbounding Emerging Dis

View full text Add to dashboard Cite

African horse sickness (AHS) is a vector-borne disease transmitted by Culicoides spp., endemic to sub-Saharan Africa. There have been many examples of historic and recent outbreaks in the Middle East, Asia and Europe. However, not much is known about infection dynamics and outbreak potential in these naive populations. In order to better inform a previously published ordinary differential equation model, we performed a systematic literature search to identify studies documenting experimental infection of naive (control) equids in vaccination trials. Data on the time until the onset of viraemia, clinical signs and death after experimental infection of a naive equid and duration of viraemia were extracted. The time to viraemia was 4.6 days and the time to clinical signs was 4.9 days, longer than the previously estimated latent period of 3.7 days. The infectious periods of animals that died/were euthanized or survived were found to be 3.9 and 8.7 days, whereas previous estimations were 4.4 and 6 days, respectively. The case fatality was also found to be higher than previous estimations. The updated parameter values (along with other more recently published estimates from literature) resulted in an increase in the number of host deaths, decrease in the duration of the outbreak and greater prevalence in vectors.

show abstract

Section: Resultsmentioning

confidence: 99%

Re‐parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search

Fairbanks

Mertens

Tildesley

et al. 2022

Transbounding Emerging Dis

View full text Add to dashboard Cite

show abstract

“…The overlapping nucleotide sequences mapped predominantly to segments encoding NS3, VP6/NS4 and VP5. Anti-AHSV NS3 antibodies have been found to occur at low concentrations in infected horses using immunoblotting (Laviada et al 1993 ), while high concentrations of anti-VP6 and VP5 antibodies were similarly detected using horse serum from early-stage infection (Martinez-Torrecuadrada et al 1997 ). Not all studies on AHSV antigenicity concur.…”

Section: Discussionmentioning

confidence: 99%

B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera

Mathebula

Faber

Wyngaardt

et al. 2017

Onderstepoort j. vet. res.

View full text Add to dashboard Cite

Identifying antigenic proteins and mapping their epitopes is important for the development of diagnostic reagents and recombinant vaccines. B-cell epitopes of African horse sickness virus (AHSV) have previously been mapped on VP2, VP5, VP7 and NS1, using mouse, rabbit and chicken monoclonal antibodies. A comprehensive study of the humoral immune response of five vaccinated horses to AHSV-4 antigenic peptides was undertaken. A fragmented-genome phage display library expressing a repertoire of AHSV-4 peptides spanning the entire genome was constructed. The library was affinity selected for binders on immobilised polyclonal immunoglobulin G (IgG) isolated from horse sera collected pre- and post-immunisation with an attenuated AHSV-4 monovalent vaccine. The DNA inserts of binding phages were sequenced with Illumina high-throughput sequencing. The data were normalised using pre-immune IgG-selected sequences. More sequences mapped to the genes coding for NS3, VP6 and VP5 than to the other genes. However, VP2 and VP5 each had more antigenic regions than each of the other proteins. This study identified a number of epitopes to which the horse’s humoral immune system responds during immunisation with AHSV-4.

show abstract

Antigenic Profile of African Horse Sickness Virus Serotype 4 VP5 and Identification of a Neutralizing Epitope Shared with Bluetongue Virus and Epizootic Hemorrhagic Disease Virus

Martı́nez-Torrecuadrada¹,

Langeveld²,

Venteo³

et al. 1999

Virology

View full text Add to dashboard Cite

African horse sickness virus (AHSV) causes a fatal disease in horses. The virus capsid is composed of a double protein layer, the outermost of which is formed by two proteins: VP2 and VP5. VP2 is known to determine the serotype of the virus and to contain the neutralizing epitopes. The biological function of VP5, the other component of the capsid, is unknown. In this report, AHSV VP5, expressed in insect cells alone or together with VP2, was able to induce AHSV-specific neutralizing antibodies. Moreover, two VP5-specific monoclonal antibodies (MAbs) that were able to neutralize the virus in a plaque reduction assay were generated. To dissect the antigenic structure of AHSV VP5, the protein was cloned in Escherichia coli using the pET3 system. The immunoreactivity of both MAbs, and horse and rabbit polyclonal antisera, with 17 overlapping fragments from VP5 was analyzed. The most immunodominant region was found in the N-terminal 330 residues of VP5, defining two antigenic regions, I (residues 151-200) and II (residues 83-120). The epitopes were further defined by PEPSCAN analysis with 12mer peptides, which determined eight antigenic sites in the N-terminal half of the molecule. Neutralizing epitopes were defined at positions 85-92 (PDPLSPGE) for MAb 10AE12 and at 179-185 (EEDLRTR) for MAb 10AC6. Epitope 10AE12 is highly conserved between the different orbiviruses. MAb 10AE12 was able to recognize bluetongue virus VP5 and epizootic hemorrhagic disease virus VP5 by several techniques. These data will be especially useful for vaccine development and diagnostic purposes.

show abstract

Serologic markers in early stages of African horse sickness virus infection

Cited by 5 publications

References 16 publications

Re‐parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search

Re‐parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search

B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera

Antigenic Profile of African Horse Sickness Virus Serotype 4 VP5 and Identification of a Neutralizing Epitope Shared with Bluetongue Virus and Epizootic Hemorrhagic Disease Virus

Contact Info

Product

Resources

About